Specialty Compared to Oncology Delivered Palliative Care for Treating Acute Myeloid Leukemia
Overview
Tab Title Description
Study type
InterventionalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 22-000288
NCT ID: NCT05237258
Sponsor Protocol Number: 21-646
About this study
The purpose of this study is to evaluate whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria - Patient:
- Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
- Patients with new diagnosis ≥ 60 years of age;
- An antecedent hematologic disorder;
- Therapy related-disease;
- Relapsed or primary refractory AML.
- Receiving treatment with either:
- intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or
- hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial.
Inclusion Criteria - Caregiver:
- Adult (≥ 18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.
Exclusion Criteria - Patient:
- Patients with a diagnosis of acute promyelocytic leukemia (APML).
- Patients with AML receiving supportive care alone.
- Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures.
- Patients seen by a palliative care clinician [MD or APP] during two hospitalizations in the six months prior to enrollment.
Eligibility last updated 11/27/23. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Jacob Strand, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available